Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26F5Y34
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,739
Award facts
- Contract value 100% obligated
- $13,738.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,738.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 16, 2026, for REPATHA 140 mg/ml SureClick auto-injector pens, with a completion date of January 20, 2026. This delivery order was not set-aside and represents a competitively awarded transaction. The place of performance is Conshohocken, Pennsylvania, which serves as the corporate office and primary distribution hub for AmerisourceBergen Drug Corp. This contract is executed under the company's parent organization, Cencora, Inc. (doing business as AmerisourceBergen), which holds a significant $999.99 billion Indefinite Delivery Contract with DLA Troop Support Medical through December 2026, serving as the primary vehicle for delivering comprehensive pharmaceutical and medical supplies to military healthcare programs globally.
REPATHA (evolocumab) is a PCSK9 inhibitor used in cardiovascular disease management for patients with high cholesterol. The delivery order reflects the Defense Logistics Agency's ongoing pharmaceutical procurement operations to support military treatment facilities and defense healthcare systems. AmerisourceBergen Drug Corp's substantial IDC with DLA Troop Support Medical demonstrates the company's critical role as a prime vendor for federal medical supply needs, encompassing specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The competitively awarded status of this delivery order, combined with the company's established infrastructure and parent company's extensive contract portfolio, indicates AmerisourceBergen's proven capability to meet federal pharmaceutical procurement requirements efficiently.
Quick answers
Who was awarded contract SPE2DR26F5Y34?
SPE2DR26F5Y34 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26F5Y34 worth?
The government has obligated $13,739 on SPE2DR26F5Y34.
Is contract SPE2DR26F5Y34 an order under another contract?
Yes. SPE2DR26F5Y34 is a delivery order under SPE2DR25D3101, an indefinite delivery contract.
Was contract SPE2DR26F5Y34 competed?
The extent of competition for SPE2DR26F5Y34 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award